Vera Therapeutics Raises $300 Million in Public Offering to Advance Immunologic Disease Pipeline
核心洞察
Vera Therapeutics successfully completed a $300 million public offering of Class A common stock, selling 7,058,824 shares at $42.50 per share.
The biotechnology company focuses on developing treatments for serious immunologic diseases, with lead candidate atacicept targeting autoimmune conditions.
Atacicept is a fusion protein that blocks BAFF (搜索) and APRIL (搜索) pathways, designed to reduce autoantibody production in diseases like IgA nephropathy and lupus nephritis (搜索).
Vera Therapeutics, a late clinical-stage biotechnology company, has successfully raised approximately $300 million through an underwritten public offering of its Class A common stock. The Brisbane, California-based company sold 7,058,824 shares at $42.50 per share, with underwriters exercising their full option to purchase an additional 920,716 shares. The offering closed on December 11, 2025.
Company Focus and Mission
Vera Therapeutics specializes in developing and commercializing transformative treatments for patients with serious immunologic diseases. The company's mission centers on advancing treatments that target the source of disease to change the standard of care for patients suffering from autoimmune conditions.
Lead Product Candidate: Atacicept
The company's primary asset is atacicept, a fusion protein administered as a subcutaneous once-weekly injection that patients can self-administer at home. Atacicept works by blocking both B-cell Activating Factor (BAFF (搜索)) and A PRoliferation-Inducing Ligand (APRIL (搜索)), which are key stimulators that drive B cells to produce autoantibodies contributing to certain autoimmune diseases.
The therapeutic is being developed for immunoglobulin A nephropathy (搜索) (IgAN) and lupus nephritis (搜索), with Vera Therapeutics evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful.
Expanding Pipeline
Beyond atacicept, Vera Therapeutics holds an exclusive license agreement with Stanford University for VT-109, described as a novel, next-generation fusion protein targeting BAFF (搜索) and APRIL (搜索). This candidate is positioned to have wide therapeutic potential across the spectrum of B-cell-mediated diseases.
The company is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients.
Financial Structure and Rights
Vera Therapeutics retains all global developmental and commercial rights to its three main assets: atacicept, VT-109, and MAU868. The recent public offering was managed by J.P. Morgan (搜索), Goldman Sachs (搜索) & Co. LLC, Evercore ISI, and Cantor as joint book-running managers, with LifeSci Capital serving as lead manager.
The successful completion of this substantial funding round positions Vera Therapeutics to advance its immunologic disease pipeline, particularly as the company continues clinical development of its lead candidate atacicept in autoimmune conditions affecting the kidney.